What's fueling the biotech engine—2010 to 2011

Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial

(2011) Bernard Zinman et al.   LANCET

Patent Watch

(2011) Charlotte Harrison   NATURE REVIEWS DRUG DISCOVERY

Cost-effectiveness of disease-modifying therapy for multiple sclerosis: A population-based study

(2011) K. Noyes et al.   NEUROLOGY

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

(2011) Fred Poordad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection

(2011) Kenneth E. Sherman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Developing the Nation's Biosimilars Program

(2011) Steven Kozlowski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection

(2011) Ira M. Jacobson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

What's fueling the biotech engine—2009–2010

(2010) Saurabh Aggarwal   NATURE BIOTECHNOLOGY

Targeted cancer therapies

(2010) Saurabh Aggarwal   NATURE REVIEWS DRUG DISCOVERY

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

What's fueling the biotech engine—2008

(2009) Saurabh Aggarwal   NATURE BIOTECHNOLOGY

The 2009 COID Recommendations for RSV Prophylaxis: Issues of Efficacy, Cost, and Evidence-Based Medicine

(2009) L. R. Krilov et al.   PEDIATRICS

What's fueling the biotech engine—2007

(2008) Saurabh Aggarwal   NATURE BIOTECHNOLOGY

Systemic lupus erythematosus in the elderly

(2007) J. Rovenský et al.   AUTOIMMUNITY REVIEWS